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7RESEARCH Open AccessIncreased levels of choline metabolites are an
early marker of docetaxel treatment response in
BRCA1-mutated mouse mammary tumors: an
assessment by ex vivo proton magnetic resonance
spectroscopy
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Background: Docetaxel is one of the most frequently used drugs to treat breast cancer. However, resistance or
incomplete response to docetaxel is a major challenge. The aim of this study was to utilize MR metabolomics to
identify potential biomarkers of docetaxel resistance in a mouse model for BRCA1-mutated breast cancer.
Methodology: High resolution magic angle spinning (HRMAS) 1H MR spectroscopy was performed on tissue
samples obtained from docetaxel-sensitive or -resistant BRCA1-mutated mammary tumors in mice. Measurements
were performed on samples obtained before treatment and at 1-2, 3-5 and 6-7 days after a 25 mg/kg dose of
docetaxel. The MR spectra were analyzed by multivariate analysis, followed by analysis of the signals of individual
compounds by peak fitting and integration with normalization to the integral of the creatine signal and of all
signals between 2.9 and 3.6 ppm.
Results: The HRMAS spectra revealed significant metabolic differences between sensitive and resistant tissue
samples. In particular choline metabolites were higher in resistant tumors by more than 50% with respect to
creatine and by more than 30% with respect to all signals between 2.9 and 3.6 ppm. Shortly after treatment (1-2 days)
the normalized choline metabolite levels were significantly increased by more than 30% in the sensitive group
coinciding with the time of highest apoptotic activity induced by docetaxel. Thereafter, choline metabolites in these
tumors returned towards pre-treatment levels. No change in choline compounds was observed in the resistant tumors
over the whole time of investigation.
Conclusions: Relative tissue concentrations of choline compounds are higher in docetaxel resistant than in sensitive
BRCA1-mutated mouse mammary tumors, but in the first days after docetaxel treatment only in the sensitive tumors
an increase of these compounds is observed. Thus both pre- and post-treatment tissue levels of choline compounds
have potential to predict response to docetaxel treatment.* Correspondence: Sjaak.vanAsten@radboudumc.nl
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Breast cancer remains the most common type of malig-
nancy and is also the second most common cause of
cancer deaths in females [1]. The main treatment modal-
ities include surgery, radiotherapy and systemic therapy.
Among the chemotherapeutic agents, docetaxel has well
established benefits in the treatment of breast cancer
[2,3]. Unfortunately, resistance to chemotherapy remains
a common problem during treatment. Many patients do
not respond to docetaxel or will cease to respond after
the initiation of therapy, either because of an inherent or
an acquired resistance, resulting in the development of
progressive disease [4]. Molecular and metabolic bio-
markers may identify docetaxel resistant and sensitive
subjects and stratify patients for better treatment op-
tions. However, thus far there are no reliable methods to
predict the response to docetaxel prior to treatment or
to identify the patients who will most likely benefit from
therapy. A shortcoming of previous attempts to identify
markers for response may be that tumors were not sub-
jected to chemo therapeutic drugs when sampled for
analysis, or treatment was given a few weeks before
sampling (neoadjuvant trials). Relevant factors, like al-
tered metabolism or apoptosis may be easier to monitor
shortly after docetaxel-induced stress.
Alterations in the metabolic composition of cells and tis-
sues represent the ultimate response of biological systems
to genetic and environmental changes. Thus, high through-
put analysis of small-molecular metabolites (metabolomics)
may uncover changes in metabolite concentrations as indi-
cators of cellular and tissue response to external stimuli
[5-10]. This offers unique opportunities to elucidate drug
response mechanisms and to identify response biomarkers.
Magnetic resonance spectroscopy (MRS) has the potential
to detect metabolic changes in a non-invasive way. For in-
stance, in 1H MR spectra obtained from breast tumors
in vivo the composite signal of the N-methyl protons of all
choline compounds (total choline or tCho) is often in-
creased compared to normal tissue. This may serve as a
biomarker to detect cancer in vivo [11]. More specifically,
this signal can be used as an indicator of response to neo-
adjuvant chemotherapy in locally advanced breast cancer
[12]. The overlapping signals of the different choline com-
pounds can be resolved in 1H High Resolution Magic Angle
Spinning (HRMAS) MRS from intact tissue samples, mea-
sured at higher magnetic field strengths [13].
To study docetaxel resistance, we used a genetically
engineered mouse model for BRCA1-mutated breast can-
cer [14]. In this model mice develop spontaneous tumors
that highly resemble their human counterpart [15]. More-
over, the docetaxel responses seen in these animals mimic
the response variability seen in patients [16]. The aim of
this study was to identify a metabolic marker for the re-
sponse to docetaxel treatment by using HRMAS MRS ontissue samples obtained from sensitive and resistant tu-
mors that develop in the BRCA1 model. Such a marker
could be useful to evaluate the effectiveness of docetaxel
treatment.
Materials and methods
Animals
Sections of T*23 sensitive (N = 14) and T*23 resistant
(N = 20) tumors from syngeneic mice (K14cre;Brca1F/F;
p53F/F), were orthotopically transplanted into a mammary
fat pad of female WT mice as described by Beekman et al.
[15]. At week three to four after transplantation, thera-
peutic intervention and sampling of tissue for HRMAS
MRS was started (tumor size of 7–10 mm in diameter).
The treatment and monitoring period of tumor bearing
mice were as described [15]. In brief, after day 0, the ani-
mals received 25 mg/kg docetaxel (Taxotere, Aventis
Pharma BV, diluted to 2.5 mg/ml in 0.9% saline) by intra-
venous tail vein injection. Tumor response was monitored
at day 0 (no treatment) and 1-2 days, 3-5 days and 6-7 days
post treatment. Biopsies for HRMAS MRS experiments
were harvested and snapshot frozen in liquid nitrogen
immediately after sacrificing the mice (n ≈ 4-7 for each
monitoring point). The treatment efficacy was evaluated by
volumetric tumor measurements (caliper measurements
and computed tomography) and by immunohistochemical
staining for apoptosis (TUNEL) [15]. All animal experi-
ments were performed in accordance with Dutch animal
welfare regulations and were approved by the local ethics
committee DEC (Dier Experimenten Commissie) from The
Netherlands Cancer Institute- Antoni van Leeuwenhoek
hospital (NKI-AvL), Amsterdam, The Netherlands.
NMR experiments
Multiple tumor sections from the different groups (n = 23
resistant, n = 19 sensitive; in 8 cases two tissue specimens
were obtained from the same xenograft) were analysed by
HRMAS MRS using a Bruker DRX 500 MHz spectrometer,
equipped with a 1H/13C HRMAS probe head, optimized for
1H sensitivity. The biopsies were gently thawed and cut
(sample weight: 4.5 to 11 mg) to fit in a 12ul sphere
(2.8 mm diameter) of a zirconia rotor. D2O was added to
fill up the sphere and to lock the B0 field. The sphere of the
MAS rotor (4 mm diameter) was closed by a teflon insert
and sealed with a Kel-F cap and then placed at an angle of
54°44” with respect to the main magnetic field. Rotating the
sample under this angle averages out the line broadening
effects of chemical shift anisotropy and dipolar coupling,
typical for spectra of samples in semi-solid state. NMR
spectra were acquired at 4°C at a magic angle spinning rate
(masr) of 4 kHz, employing the 1D 1H NMR CPMG (Carr
Purcell Meiboom Gill) [17] sequence (T2 filter/TR = 30/
5000 ms) [18]. The 90° pulse was optimized per sample
ranging from 6.2 to 9.5 μs. A T2 filter of 30 ms was used to
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with short transverse relaxation times (T2 times below
30 ms). An interval of 1 rotor period (1/masr) between the
180° pulses enabled optimal suppression of J-modulation
effects and chemical shift anisotropy, and minimized the
contribution of diffusion to relaxation processes. The water
resonance was suppressed by presaturation. With an excita-
tion bandwidth of 6000 Hz collected in 16 K complex
points the acquisition time was 1.36 seconds, and with 256
transients collected every 5 seconds, the total measurement
time was ~25 minutes. The whole procedure from the start
of thawing until the end of acquisition was less than
45 minutes.Data processing and analysis
The MR spectra, apodized with a 0.3 Hz exponential
filter, were analyzed in two different ways. First, the cor-
relation between metabolic profiles and treatment effect
was assessed by multivariate data analysis, performed in
MATLAB (Version 7.9.0; The Math Works, Natick, MA,
USA). To exclude variations in lipid signals arising from
the mammary fat pad, the spectral region between 2.9–
4.5 ppm containing the majority of the small molecular
metabolites was selected in the multivariate analysis. In
addition the region from 3.6 to 3.7 ppm was excluded to
discard contaminating ethanol signals from the analysis.
Spectra were normalized by setting the total signal inte-
gral of this spectral area to a constant value (=1) for all
spectra to minimize differences in sample weight. Unsuper-
vised principal component analysis (PCA) was performed
using PLS_Toolbox v5.8.3 (Eigenvector Research, Manson,
WA, USA). PCA reduces the dimensionality of the data
and summarizes the structure of multiple MR spectra in
score plots and loading profiles. The variance structure of
the data is explained by linear combinations of the variables
called principal components (PCs). The first PCs will be in
the direction explaining most of the variance in the data
set. In the score plot of the PCs, samples with a similar
metabolic profile will cluster. Loading profiles display the
importance of each variable within the PC.
In the second approach, the spectra were subjected to
a peak fitting procedure. Based on the results of the PCA
analysis we focused on the spectral range from 2.9 –
3.6 ppm. The metabolite signals of glycerophosphocholine
(GPC), phosphocholine (PCho), choline (Cho), and creat-
ine (Cr) were fitted with Lorentzian lines, using Bruker
Topspin software. The spectral areas determined by peak
fitting were normalized to the signal integral of Cr. Since
Cr, as an internal reference, could be influenced by the do-
cetaxel treatment [19], the spectral areas of the choline
signals were also normalized to the total area (integral) of
all signals in the 2.9 – 3.6 ppm region. The results were
statistically analyzed by a two-tailed unpaired t-test.Results
Metabolic differences between docetaxel resistant and
sensitive tumors before treatment
A comparison of spectra obtained by 1H HRMAS MRS
of resistant and sensitive breast cancer tissue shows
some clear spectral differences between 3.1 and 3.4 ppm
(Figure 1A). Analysis by PCA of spectra obtained before
the start of treatment (day 0), revealed that the tumors
indeed were metabolically distinct (Figure 1B). All choline
groups including phosphocholines (PCho), free choline
(Cho) and glycerophosphocholines (GPC) were higher in
resistant than in sensitive tumors. In contrast, PCA indi-
cated that sensitive control tumors had higher levels of gly-
cine (Gly), taurine (Tau) and Cr. For other metabolites with
signals in the spectral region between 2.9 and 4.5 ppm,
such as myo-inositol and ethanolamine, no differences
could be detected between the two tumor lines.
Spectral peak fitting confirmed that the sensitive
tumors had significantly lower levels of choline metabo-
lites than resistant tumors at day 0 (Figure 2A-F and
Table 1A (p < 0.05)).
Effect of treatment
As previously reported, tumor growth after docetaxel
treatment significantly decreased in the sensitive tumors,
and TUNEL staining showed a significant increase of
apoptotic cells in these tumors with the highest increase
at day 1-2, while this was not the case in the resistant
tumors [15]. The biopsies from sensitive and resistant
strains were evaluated separately by principal compo-
nent analysis. PCA score plots of the sensitive strains
(Figure 3A) showed a trend towards clustering based on
the post treatment interval. The metabolic profiles of
sensitive tumor samples obtained within 48 hours of
treatment were characterized by higher levels of PCho
compared to untreated controls. At 3-5 days post treat-
ment, samples contained higher amounts of lactate, but
for samples obtained at 6-7 days post treatment there
was no difference with pre-treatment and 1-2 day post
treatment groups. PCA of the resistant strain showed no
tendency toward clustering based on the post treatment
intervals (Figure 3B).
To assess the significance of changes in choline metab-
olites detected in the exploratory analysis by PCA, the
signals of GPC, PCho, Cho were quantified with respect
to Cr and with respect to the total signal integral of the
spectral region from 2.9 to 3.6 ppm (Figure 2). The p-
values of the significant differences are listed in Table 1B.
For sensitive tumor tissues, the ratios of total choline
(tCho), (GPC+ PCho) and of Cho to Cr were significantly
increased (p < 0.005) at one to two days post-treatment
(Figure 2A-C). In agreement with this observation also a
significant increase was found for the integrals of these
choline metabolite signals normalized to the total signal
Figure 1 1H HRMAS spectra and Principal Component Analysis (PCA) of control tumor samples. A: The mean spectra of resistant tumor (red)
show increased choline compounds compared to those of sensitive tumors (blue). B: Biplot [42] showing PCA analysis of HRMAS spectra. Docetaxel
sensitive samples are shown with black triangle and resistant samples with squares. Arrows are drawn based on the loading plots to show the
important metabolites responsible for the demarcation between the groups. Resistant samples have higher levels of GPC, PCho and Choline.
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three to five days post-treatment, the signal integral of
these metabolites compared to that of creatine and to
the total signal integral (over 2.9 – 3.6 ppm) decreased
for the sensitive tumors (Figure 2A-F). The choline
metabolite levels relative to creatine at three to fiveFigure 2 Choline compound over creatine signal ratios (A-C) and norm
and sensitive tumor tissue samples pre- and post-treatment. Docetaxe
at day 0 and after treatment at time points 1-2, 3-5 and 6-7 days. Statistica
**p < 0.01). The number of samples of resistant and sensitive tumor tissue fdays post-treatment were still higher compared to the
pre-treatment levels (Figure 2A-C), but for these levels
relative to the total signal integral (2.9-3.6 ppm) the
values were not significantly different from those before
treatment (Figure 2D-F). At six to seven days post
treatment there were no further significant changes inalized choline compound integrals (D-F) of docetaxel resistant
l resistant and sensitive tumor samples were monitored pretreatment
l significant differences are indicated with an asterisk (*p < 0.05,
or the different time points were: [7,5], [7,5], [5,5] and [4,4].
Table 1 P-values of metabolite differences
A) P values of metabolite differences between resistant and sensitive tumors
P (Resist-Sens) tCho/Cr (GPC+PC)/Cr Cho/Cr tCho GPC+PC Cho
0d 0.001 0.003 0.005 0.026 - 0.006
1-2d 0.025 0.041 - - - -
3-5d - - - - - 0.029
6-7d - - - - - 0.033
B) P values of metabolite differences between monitored time points after docetaxel treatment
P (time) 0d 1-2 3-5d 0d 1-2d 3-5d 0d 1-2d 3-5d
tCho/Cr 0.0009 - 0.003 (GPC+PC)/Cr 0.004 - 0.013 Cho/Cr 0.0001 - 0.006
tCho/Cr - 0.021 - (GPC+PC)/Cr - 0.028 - Cho/Cr - 0.023 -
Cho/Cr - 0.041 -
tCho 0.020 - 0.033 (GPC+PC) 0.038 - - Cho 0.019 - 0.019
Significance of choline metabolite signal differences (p-values), corresponding with Figure 2.
A:between the resistant and sensitive tumor tissue samples of metabolite signals with respect to the creatine signal and with respect to the total integral of all
signals between 2.9 and 3.6 ppm. If no number is presented the differences were not significant.
B:between the measurement time points, assessing treatment effect of the resistant and sensitive tumor tissue samples. Numbers for sensitive (regular) and
resistant (italic) tumor tissue represent the p-values between the overlapping time points.
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tive group compared to the levels at three to five days
in this group.
In contrast to these responses for the sensitive tumors,
the signal levels of all choline compounds in the docetaxel
resistant tumors did not change significantly during the
entire time course after treatment (Figure 2). The mice in
which two specimens were obtained for HRMAS showed
comparable results within the standard deviation of the
subgroups, except for one sensitive specimen at day 7, that
had lower choline signals than the mean. Glycine and tau-
rine levels did not change during the post-treatment period
in both subgroups except for an increase of about 13% ofFigure 3 Principal Component Analysis (PCA) biplots [42] of the sensi
differences in the metabolic profiles depending on the number of days aft
clusters based on the number of days after treatment (A) while the resistanthe normalized taurine level at days 3 – 7 in the docetaxel
sensitive group (p = 0.034).
Discussion
In this study we used a well-documented mouse breast
cancer model that develops spontaneous tumors which
share key features with BRCA1- associated breast cancer
in humans [20]. We observed that tissue of docetaxel
sensitive tumors in this model have a lower level of cho-
line compounds compared to the resistant tumors. How-
ever, after docetaxel treatment the sensitive tumors
showed a transient increase in these compounds, while
their level remained stable in the resistant tumors. Thesetive (A) and resistant (B) strains of mouse models. Plots show the
er the administration of docetaxel. The sensitive strain shows distinct
t strain does not (B) show such clusters.
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ment were recorded by HRMAS MRS of tissue samples,
which is a method that can be employed in the clinic to
assess metabolites in fine-needle biopsies [18,21].
One of the major obstacles in the treatment of breast
cancer is the effective application of chemotherapy.
Selecting treatments based on the clinical and molecular
characteristics of the tumor have the potential for an indi-
vidualized, more effective, and less toxic therapy. However,
in clinical decision making involving tumor treatment with
docetaxel a good biomarker that can predict response to
this drug is lacking [4]. Previously, we have tested if
Annexin-V (99mTc-AnxV) uptake values in our mouse
tumor model, as measured by Single Photon Emission
Computed Tomography (SPECT), could serve this purpose,
but the uptake values for sensitive and resistant tumors
were overlapping [15]. Here we identified an elevated level
of choline metabolites (GPC, PCho, Cho) as a potential bio-
marker to differentiate between tumors sensitive and resist-
ant to docetaxel treatment. Converting this result into a
clinically useful response indicator still has a long way to
go, as it requires the identification and validation of reliable
threshold values for pretreatment choline containing
compounds in patients, that may be able to distinguish
between responders and non-responders. The applica-
tion of HRMAS MRS in studies using fine-needle or
core biopsy samples from breast cancer patients under
docetaxel treatment, may be useful to establish such
cutoff values [21]. Successful development and implemen-
tation of metabolomics based detection of docetaxel resist-
ant breast cancers may allow clinicians to plan optimal
therapies for the right patient.
After administration of docetaxel, there was a clear
time dependent change in the metabolic patterns of
sensitive tumors as compared to resistant tumors. Multi-
variate analysis revealed an increase in choline metabo-
lites (PCho) in the sensitive tumors, which was more
clearly observed by metabolite signal quantification. This
showed increased Cho and (GPC + PCho) signals nor-
malized to Cr or to the total signal integral between 2.9
and 3.6 ppm at 1 – 2 days post-treatment. In the follow-
ing days this increase was (partly) reversed. This clearly
identifies the increased levels of choline compounds as a
early marker for the response to docetaxel treatment in
the BRCA-1 tumor model.
Apoptosis or programmed cell death is observed at an
enhanced rate in tumors responding to various cytotoxic
drugs that have different mechanisms of action [22]. It is
well-known that docetaxel also induces apoptosis in can-
cer cells although the precise molecular mechanism is
still unclear [23-26]. Whereas choline deficiency is found
to induce apoptosis in some cell systems [27,28], the
results of our study on treatment sensitive BRCA-1 mu-
tated tumors indicate that increased apoptotic activity bydocetaxel treatment is associated with an increase in
choline metabolites. There are two plausible explanations
for this increase. First, the metabolic changes are merely
reflecting an unspecific association with apoptosis or cell
death. The second possibility is that apoptosis induced by
docetaxel is mediated by alterations in metabolic pathways
involving choline compounds. For instance it was demon-
strated that the induction of apoptosis by different agents
in two different cell lines (HL-60 and CHO-K1) increased
the level of CDP-choline [29]. Changes in PCho and
phospho-ethanolamine (PE) were not consistent across dif-
ferent apoptotic inducers. In a study of human neutrophils
undergoing TNF-alpha induced apoptosis, an increase in
PCho using MRS and HPLC was observed [30]. This effect
on PCho content may indicate activation of phospholipases
associated with apoptosis or a selective failure of phosphat-
idylcholine synthesis. An association between increased
choline compounds and apoptosis shortly after therapy was
also found in an ex vivo MR study of rat glioma under gene
therapy [31]. Cancer therapy by histone deacetylase inhib-
ition, known to induce apoptosis [32], increases PCho levels
in tumor cells and xenografts [25,33]. Since the changes in
choline metabolites are insignificant in resistant BRCA-1
tumors, there is a good reason to hypothesize that the
observed changes in choline containing metabolites
are linked to the docetaxel response of the sensitive
tumors and possibly add to its mechanism of action
including its well-known effect on microtubules [4].
The role of choline containing compounds in breast
cancer development and progression is widely recog-
nized. Their tissue levels are used as biomarkers of re-
sponse to therapy [11]. Unlike most of the studies
reporting a reduction in choline containing metabolites
in response to therapy of breast cancer [34-37], in this
study we observed an increase in choline metabolites,
as an early response after chemotherapy in the doce-
taxel sensitive tumors. This discrepancy may be due to
different times between metabolic MR observation and
therapy or to the dosage of the used drug (vide infra)
and to its specific interaction with (selected) breast
tumor types [25,38]. More in line with our findings are
the observation of increased GPC and PCho levels in
MCF7 breast cancer cells after histone deacytelase
inhibition, which was assigned to an elevated choline
transporter and choline kinase activity [39].
In this study we used a single animal model with a spe-
cific genetic pattern with a single dosage regimen and
hence can impart certain limitations. Although animal
models offer a practical solution to explore the tumour
biology, their ability to mimic the extremely complex
aspects of human carcinogenesis, progression and patho-
physiology are limited. Therefore it is necessary to validate
these findings in further clinical studies; especially where
other factors such as tumor heterogeneity and combination
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shown that the concentration of docetaxel will influence its
mechanism of action at the molecular level [40]. A low
dosage caused aberrant mitosis followed by late necrosis
where as a higher dosage resulted in mitotic arrest and
apoptosis. Therefore, it is needed to further evaluate the
response to different dosage regimens in animal model
studies. The inherent limitation of ex-vivo studies include
potential metabolic changes occurring during biopsy pro-
cedures, but all biopsy samples in this study were snapshot
frozen to minimize such changes. Owing to overlap of
GPC and PCho signals in some of the proton MR spectra,
we combined the integrals of these signals. With 31P
HRMAS MRS it is possible to resolve resonances for these
individual metabolites, which could improve the specificity
of treatment prediction [41].
Conclusions
In conclusion, this study shows that 1H HRMAS MRS
can distinguish between docetaxel sensitive and resistant
BRCA1-mutated mouse mammary tumors because they
are metabolically distinct. Furthermore, in docetaxel sensi-
tive tumors an increase in choline containing metabolites is
observed at 1-2 days after the initiation of therapy, which
corresponds to the time of maximum apoptotic activity in
these tumors [15]. Relative pre-treatment tissue concentra-
tions of choline compounds are higher in docetaxel resist-
ant than in sensitive tumors. These results indicate that
metabolomics by HRMAS MRS may predict and monitor
chemotherapy response in docetaxel treatment and might
enable a more efficient breast cancer treatment procedure.
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